Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Epithelial–mesenchymal transition (EMT) has been shown to play a critical role in tumor
development from initiation to metastasis. EMT could be regarded as a continuum, with …

Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-
1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor …

Background Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody
YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models …

Metal‐based nanomaterials have attracted broad attention recently due to their unique
biological physical and chemical properties after entering tumor cells, namely biological …

PURPOSE Immunotherapy and chemotherapy combinations have shown activity in
endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than …

Background Modulating the DNA damage response and repair (DDR) pathways is a
promising strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral …

As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects …

Epithelial ovarian cancer (EOC) is among the top five causes of cancer-related death in
women, largely reflecting early, prediagnosis dissemination of malignant cells to the …